Clinical use in COVID-19
Dipyridamole is an inhibitor of phosphodiesterase 3 and 5, thereby it
increases intracellular cAMP and/or cGMP in platelets and inhibits
platelet aggregation (209). Besides, it
has antiviral features against several viruses
(210,211). Dipyridamole as an adjunctive
therapy was demonstrated to be associated with decreased D-dimer levels
in COVID-19 (212).